Case Study: Novartis improves patient education and first-dose support with Valtech's My First Dose app

Novartis improves first-dose patient education with Valtech’s 6-hour My First Dose app

Novartis, one of the world's largest multinational pharmaceutical companies, faced the challenge of building an international app for their product Gilenya that complied with pharmaceutical regulations across multiple countries. They needed an innovative way to manage the first-dose observation experience for patients and healthcare professionals. They partnered with vendor Valtech to develop a solution.

Valtech developed "My First Dose," an iPad-based edutainment tool that educated patients during their observation period. The solution was responsive and dynamic, allowing for immediate content updates. The Valtech solution received very positive feedback from all users and was proven to provide an overall positive first-dose experience. It was successfully piloted in Denmark, where independent market research showed all patients and nurses would advocate for its use.

Novartis